The use of an amino acid formula containing synbiotics in infants with cow’s milk protein allergy—effect on clinical outcomes
This publication examines the impact of using an amino acid formula containing pre- and probiotics (synbiotics) in infants with cow's milk protein allergy (CMPA). The retrospective matched cohort study analyzed data from The Health Improvement Network database, comparing 148 infants prescribed either AAF-Syn (containing probiotic Bifidobacterium breve M16-V and prebiotics) or AAF without synbiotics.
The study found that AAF-Syn was associated with significant reductions in symptoms, infections, medication prescriptions, and healthcare contacts compared to AAF. Infants prescribed AAF-Syn had a higher probability of achieving asymptomatic management without hypoallergenic formula and a shorter clinical course of symptoms. AAF-Syn was also associated with potential cost-savings per infant over the clinical course of symptoms.
The study provides evidence consistent with clinical trials, suggesting that AAF-Syn may offer clinical and healthcare benefits with potential economic impact, possibly due to its effect on the gut microbiome. Further research is needed to explore this relationship.
Downloads
Please sign in or create a free account to download files.
The use of an amino acid formula containing synbiotics in infants with cow’s milk protein allergy—effect on clinical outcomes
Topics
This content is from a third party site.
This content is hosted on an external website. Clicking on the button will open the website in a new browser tab.